- Report
- March 2025
- 175 Pages
Global
From €4256EUR$4,490USD£3,555GBP
- Report
- May 2024
- 134 Pages
Global
From €6160EUR$6,499USD£5,146GBP
- Report
- March 2024
- 118 Pages
Global
From €4265EUR$4,500USD£3,563GBP
- Report
- January 2025
- 82 Pages
Saudi Arabia
From €3317EUR$3,500USD£2,771GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
- Report
- April 2025
- 50 Pages
Global
From €2512EUR$2,650USD£2,098GBP
- Report
- November 2021
- 620 Pages
Global
From €3791EUR$4,000USD£3,167GBP
Raltegravir is an antiretroviral drug used to treat HIV infection. It is a member of the integrase inhibitor class of drugs, which work by blocking the action of the HIV enzyme integrase, preventing the virus from replicating. Raltegravir is used in combination with other antiretroviral drugs to treat HIV infection. It is also used to prevent HIV infection in people who are at high risk of contracting the virus.
Raltegravir is a widely used drug in the infectious diseases drugs market. It is used in combination with other antiretroviral drugs to treat HIV infection, and is also used to prevent HIV infection in people who are at high risk of contracting the virus. It is generally well tolerated and has few side effects.
Some companies in the Raltegravir market include Merck & Co., Inc., Gilead Sciences, Inc., Bristol-Myers Squibb Company, and ViiV Healthcare. Show Less Read more
